Jubilant Pharmova Limited — Investor Meet, 31-07-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Jubilant Pharmova's Q1 FY26 revenue grew 10% YoY to Rs. 1,901 Cr., with EBITDA up 14% to Rs. 302 Cr. and normalized PAT soaring 48% to Rs. 103 Cr. Radiopharma benefits from Ruby-Fill® and new products, while Radiopharmacies are expanding PET. CDMO Sterile Injectables capacity growth is ahead of expectations, set to boost future revenue. CRDMO is scaling large pharma contracts. Generics showed significant margin improvement. The company is advancing two novel drug programs in clinical trials. Management holds a confident outlook towards Vision 2030 goals of 2x revenue and higher margins.